Nasopharyngeal carcinoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Nasopharyngeal carcinoma}}
{{Nasopharyngeal carcinoma}}
{{CMG}} {{AE}}{{Homa}}{{Faizan}}
==Overview==
Laboratory findings consistent with the diagnosis of nasopharyngeal carcinoma include an elevated concentration of [[serum]] [[EBV]] titer. [[Plasma]] [[Epstein Barr virus|EBV]] [[DNA]] load, [[EBV]] [[viral]] [[capsid]] [[antigen]], assessment of [[Epstein Barr virus|EBV]] in the pathologic specimens, [[Complete blood count]], [[Urea]] and [[creatinine]], [[Electrolyte|electrolytes]], [[Liver function tests]], [[Calcium]] and [[phosphate]], and [[Alkaline phosphatase]] are the tests which should be done for the [[diagnosis]] and assessment of [[tumor]] invasion, and [[differentiation]] of [[tumor]].
==Laboratory Findings==
* An positive [[concentration]] of serum [[Epstein Barr virus|EBV]] [[DNA]] is [[diagnostic]] of nasopharyngeal carcinoma.<ref name="WeiSham2005">{{cite journal|last1=Wei|first1=William I|last2=Sham|first2=Jonathan ST|title=Nasopharyngeal carcinoma|journal=The Lancet|volume=365|issue=9476|year=2005|pages=2041–2054|issn=01406736|doi=10.1016/S0140-6736(05)66698-6}}</ref><ref name="WeiJin2014">{{cite journal|last1=Wei|first1=Qing-Yi|last2=Jin|first2=Hekun|last3=Xie|first3=Xiaoxue|last4=Wang|first4=Hui|last5=Hu|first5=Jun|last6=Liu|first6=Feng|last7=Liu|first7=Zhigang|last8=Zhou|first8=Jumei|last9=Zhang|first9=Yingying|last10=Xi|first10=Xuping|last11=Hu|first11=Bingqiang|last12=Liao|first12=Yuping|last13=Tang|first13=Jingtian|title=ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma|journal=PLoS ONE|volume=9|issue=7|year=2014|pages=e101256|issn=1932-6203|doi=10.1371/journal.pone.0101256}}</ref><ref name="LinMeng2014">{{cite journal|last1=Lin|first1=De-Chen|last2=Meng|first2=Xuan|last3=Hazawa|first3=Masaharu|last4=Nagata|first4=Yasunobu|last5=Varela|first5=Ana Maria|last6=Xu|first6=Liang|last7=Sato|first7=Yusuke|last8=Liu|first8=Li-Zhen|last9=Ding|first9=Ling-Wen|last10=Sharma|first10=Arjun|last11=Goh|first11=Boon Cher|last12=Lee|first12=Soo Chin|last13=Petersson|first13=Bengt Fredrik|last14=Yu|first14=Feng Gang|last15=Macary|first15=Paul|last16=Oo|first16=Min Zin|last17=Ha|first17=Chan Soh|last18=Yang|first18=Henry|last19=Ogawa|first19=Seishi|last20=Loh|first20=Kwok Seng|last21=Koeffler|first21=H Phillip|title=The genomic landscape of nasopharyngeal carcinoma|journal=Nature Genetics|volume=46|issue=8|year=2014|pages=866–871|issn=1061-4036|doi=10.1038/ng.3006}}</ref><ref>{{Cite journal
| author = [[Peng Zhang]], [[Song-Ke Wu]], [[Ying Wang]], [[Zi-Xuan Fan]], [[Chu-Rong Li]], [[Mei Feng]], [[Peng Xu]], [[Wei-Dong Wang]] & [[Jin-Yi Lang]]
| title = p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study
| journal = [[Oncology letters]]
| volume = 9
| issue = 1
| pages = 113–118
| year = 2015
| month = January
| doi = 10.3892/ol.2014.2631
| pmid = 25435943
}}</ref>
* The [[laboratory]] tests which should be done for the [[diagnosis]] and assessment of [[tumor]] invasion, and [[differentiation]] of [[tumor]] are:<ref name="PastorLopez Pousa2017">{{cite journal|last1=Pastor|first1=M.|last2=Lopez Pousa|first2=A.|last3=del Barco|first3=E.|last4=Perez Segura|first4=P.|last5=Astorga|first5=B. Gonzalez|last6=Castelo|first6=B.|last7=Bonfill|first7=T.|last8=Martinez Trufero|first8=J.|last9=Grau|first9=J. Jose|last10=Mesia|first10=R.|title=SEOM clinical guideline in nasopharynx cancer (2017)|journal=Clinical and Translational Oncology|volume=20|issue=1|year=2017|pages=84–88|issn=1699-048X|doi=10.1007/s12094-017-1777-0}}</ref><ref name="Brennan2006">{{cite journal|last1=Brennan|first1=Bernadette|title=Nasopharyngeal carcinoma|journal=Orphanet Journal of Rare Diseases|volume=1|issue=1|year=2006|issn=1750-1172|doi=10.1186/1750-1172-1-23}}</ref><ref>{{Cite journal
| author = [[Muhyi Al-Sarraf]] & [[Maryada S. Reddy]]
| title = Nasopharyngeal carcinoma
| journal = [[Current treatment options in oncology]]
| volume = 3
| issue = 1
| pages = 21–32
| year = 2002
| month = February
| pmid = 12057084
}}</ref>
** [[Plasma]] [[Epstein Barr virus|EBV]] [[DNA]] load by [[Polymerase chain reaction|PCR]]
** [[EBV]] [[viral]] [[capsid]] [[antigen]]
** Detection of [[Epstein Barr virus|EBV]] in the pathologic specimens by immunohistochically [[staining]] for latent membtane protein (LMP) or  [[in situ]] [[hybridization]] for [[Epstein Barr virus|EBV]]-encoded [[RNA]] (EBER)
** [[Complete blood count]] (CBC)
** [[Urea]] and [[creatinine]]
** [[Electrolyte|Electrolytes]]
** [[Liver function tests]]
** [[Calcium]] and [[phosphate]]
** [[Alkaline phosphatase]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Disease]]
 
[[Category:Needs content]]
[[Category:Up-To-Date]]
[[Category:Types of cancer]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Otolaryngology]]

Latest revision as of 22:53, 29 July 2020

Nasopharyngeal carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nasopharyngeal carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nasopharyngeal carcinoma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nasopharyngeal carcinoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nasopharyngeal carcinoma laboratory findings

CDC on Nasopharyngeal carcinoma laboratory findings

Nasopharyngeal carcinoma laboratory findings in the news

Blogs on Nasopharyngeal carcinoma laboratory findings

Directions to Hospitals Treating Nasopharyngeal carcinoma

Risk calculators and risk factors for Nasopharyngeal carcinoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]

Overview

Laboratory findings consistent with the diagnosis of nasopharyngeal carcinoma include an elevated concentration of serum EBV titer. Plasma EBV DNA load, EBV viral capsid antigen, assessment of EBV in the pathologic specimens, Complete blood count, Urea and creatinine, electrolytes, Liver function tests, Calcium and phosphate, and Alkaline phosphatase are the tests which should be done for the diagnosis and assessment of tumor invasion, and differentiation of tumor.

Laboratory Findings

References

  1. ↑ Wei, William I; Sham, Jonathan ST (2005). "Nasopharyngeal carcinoma". The Lancet. 365 (9476): 2041–2054. doi:10.1016/S0140-6736(05)66698-6. ISSN 0140-6736.
  2. ↑ Wei, Qing-Yi; Jin, Hekun; Xie, Xiaoxue; Wang, Hui; Hu, Jun; Liu, Feng; Liu, Zhigang; Zhou, Jumei; Zhang, Yingying; Xi, Xuping; Hu, Bingqiang; Liao, Yuping; Tang, Jingtian (2014). "ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma". PLoS ONE. 9 (7): e101256. doi:10.1371/journal.pone.0101256. ISSN 1932-6203.
  3. ↑ Lin, De-Chen; Meng, Xuan; Hazawa, Masaharu; Nagata, Yasunobu; Varela, Ana Maria; Xu, Liang; Sato, Yusuke; Liu, Li-Zhen; Ding, Ling-Wen; Sharma, Arjun; Goh, Boon Cher; Lee, Soo Chin; Petersson, Bengt Fredrik; Yu, Feng Gang; Macary, Paul; Oo, Min Zin; Ha, Chan Soh; Yang, Henry; Ogawa, Seishi; Loh, Kwok Seng; Koeffler, H Phillip (2014). "The genomic landscape of nasopharyngeal carcinoma". Nature Genetics. 46 (8): 866–871. doi:10.1038/ng.3006. ISSN 1061-4036.
  4. ↑ Peng Zhang, Song-Ke Wu, Ying Wang, Zi-Xuan Fan, Chu-Rong Li, Mei Feng, Peng Xu, Wei-Dong Wang & Jin-Yi Lang (2015). "p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study". Oncology letters. 9 (1): 113–118. doi:10.3892/ol.2014.2631. PMID 25435943. Unknown parameter |month= ignored (help)
  5. ↑ Pastor, M.; Lopez Pousa, A.; del Barco, E.; Perez Segura, P.; Astorga, B. Gonzalez; Castelo, B.; Bonfill, T.; Martinez Trufero, J.; Grau, J. Jose; Mesia, R. (2017). "SEOM clinical guideline in nasopharynx cancer (2017)". Clinical and Translational Oncology. 20 (1): 84–88. doi:10.1007/s12094-017-1777-0. ISSN 1699-048X.
  6. ↑ Brennan, Bernadette (2006). "Nasopharyngeal carcinoma". Orphanet Journal of Rare Diseases. 1 (1). doi:10.1186/1750-1172-1-23. ISSN 1750-1172.
  7. ↑ Muhyi Al-Sarraf & Maryada S. Reddy (2002). "Nasopharyngeal carcinoma". Current treatment options in oncology. 3 (1): 21–32. PMID 12057084. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Nasopharyngeal_carcinoma_laboratory_findings&oldid=1641118"